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Should Patients with Medullary Thyroid Carcinoma Undergo 
Extensive Lymph Node (Re)Operation to Improve Long-term 
Survival? 
Caro Brumsen,* Harm R. Haak,* Bernard M. Goslings,* and Cornelis J. H. van de Velde^  
To investigate the role of primaiy and/or secondary modified radical neck dissection (MRND) in 
patients with medullary thyroid carcinoma (MTC). follow-up data on 43 patients operated on between 
1972 and 1983 were analyzed retrospectively; patients included 16 with sporadic MTC (group 1) and 
27 with muhiple endocrine neoplasia type 2 (group 2). Primary surgical therapy consisted of (near-j 
total thyroidectomy and limited lymph node dissection: one patient in group I and two in group 2 
undem'ent primary MRND. Positive nodes were found in nine patients of group 1 and in 12 of group 
2. Calcitonin (CT) was raised postoperatively in 11 group I patients, who all died (four after 
additional MRND). Postoperative CT was normal in the four survivors of group 1. In group 2. post-
operative CT was raised in 15 patients, including tho.se who had MRND and in four apparently node-
negative patients. Three of them underwent additional MRND, which was successful in one case. One 
patient in this group died ofthe disease: two patients developed elevated CT levels during follow-up, 
whereas in one, CT normalized spontaneously. In conclusion, the role of extensive lymph node 
surgery in patients with more than limited lymph node involvement or elevated postoperative CT 
levels remains to be established. (Henry Ford Hosp MedJ 1992;40:271-5) 
Medullary thyroid carcinoma (MTC) may occur as a part of multiple endocrine neoplasia (MEN) type 2A or 2B, as 
well as in sporadic nonhereditary cases. This carcinoma arises in 
the parafollicular C-cells that produce calcitonin (CT), which 
provides an excellent parameter for follow-up. 
The primary treatment is surgical with general agreement that 
a total thyroidectomy should be performed. However, questions 
have been raised regarding the type of lymph node dissection 
which should be utilized: several authors (1-3) advise primary 
elective modified radical neck dissection (MRND): others dis-
agree, arguing that MRND can never be radical (4), or does not 
improve prognosis (5), and that central neck dissection suffices 
(6-8). In addition, MRND is more mutilating and time-consum-
ing than only removing the regional lymph nodes. However, 
most authors agree that MRND or even radical neck dissection 
(9) is mandatory if cervical lymph nodes are found to be positive 
(8,10-13). By meticulous microdissection of nonpalpable lymph 
nodes, a secondary MRND can lead to normalization of CT lev-
els even several years after primary operation (14). 
Would it not therefore be possible to do only limited lymph 
node surgery, i.e., clearance ofthe central neck area, at primary 
operation and reoperate on those patients whose CT levels re-
main high postoperatively? 
To answer this question we reviewed our own patient mate-
rial with the aim to 1) identify a subgroup with normal CT val-
ues postoperatively who did well without MRND, 2) see 
whether additional MRND was useful in patients with elevated 
CT, and 3) look at the course of the disease of those with ele-
vated postoperative CT levels who were not reoperated on. 
Patients and Methods 
The records of all 43 patients with histologically proven 
MTC—16 with sporadic disease (group 1), 24 with MEN 2A 
and 3 with MEN 2B (group 2)—who were operated on between 
1972 and 1983 were reviewed for information about age at diag-
nosis, tumor status, lymph node metastasis, type of thyroid and 
lymph node surgery, clinical course, survival, and CT values 
immediately postoperative and during follow-up. 
Patient characteristics are shown in Table 1. As there were 
few patients with the MEN 2B syndrome, the results of the MEN 
2A and MEN 2B patients were combined. A comparison was 
made between the group with sporadic disease and the group 
with hereditary MTC. 
All patients received surgery, but the type of operative proce-
dure varied. In group 1, at first operation a hemithyroidectomy 
was performed three times and a (near-)total thyroidectomy six 
times. In two patients the operation was not radical and in five 
patients only a biopsy was taken. After histological diagnosis of 
MTC, some patients were reoperated on. This finally resulted in 
13 (near-)total thyroidectomies in this group and tiiree nonradi-
cal operations. Lymph node surgery consisted of taking out the 
pre- and paratracheal (central) nodes, as well as limited dissec-
tion picking out suspicious-looking nodes in the lateral and me-
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Table 1 
Patient Characteristics 
Group 1 Group 2 
Sporadic MTC MEN 2A MEN 2B 
Number of patients 16 24 3 
Sex (M:F) 7:9 12:12 0:3 
Age at diagnosis (yrs) 58 ± 14 24 ± 13 
CT level at presentation 
elevated 12 20 






< 1 cm 4 
> I cm 10 
— 
bilateral 2 21 
locally invasive 4 2 
Lymph node stage 
none 7 16 
homolateral 2 7 
bilateral 3 4 
fixed/extraregional 4 
— 
*0perated on after conversion to elevated CT levels. 
Table 2 
Type of Primary Lymph Node Surgery in 
Relation to Postoperative CT Level 
Group 1 Group 2 
CT CT CT CT 
Normal Elevated Normal Elevated 
Biopsy only 4* 1 
Pre- and paratracheal nodes 4 4 t 9 4t 
Picking out homolaterally§ — I 1 411 
Picking out bilaterally§ I 1 211 
Extended regional 1 — 3 
MRND 1 — 
— 2 
Total 5 11 12 15 
*Three patients underwent unsuccessful secondary MRND 
tOne patient underwent unsuccessful secondary MRND. 
tOne patient underwent successful MRND shortly postoperative. 
5As well as removal of pre- and paratracheal nodes. 
llOne patient in both groups ur derwent unsuccessful secondary MRND. 
diastinal compartments (Table 2). From 1983 on, we adapted a 
compartment-oriented approach in lymph node dissection, 
which implies that a microdissection was done of the central 
compartment, and MRND was peribrmed on the side(s) where 
positive lymph nodes were found. Eight times only the pre- and 
paratracheal nodes were taken out, because these patients had no 
macroscopically suspicious lymph nodes; MRND was done 
once at primary operation. 
In group 2, 26 patients underwent a (near-)total thyroidec-
tomy; in one patient the operation was locally not radical. Type 
of lymph node surgery was basically the same as in group 1; in 
this group two patients had MRND, and in 13 cases only the 
central nodes were removed. 
CT was measured by means of a radioimmunoassay which 
was developed in our own department (15); from 1984 on, a 
commercial kit (Byk/Sangtec, Dietzenbach, Germany) was 
used, which gave comparable results (16). 
Patients in the MEN 2 families were identified by demonstra-
tion of a clearly elevated stimulated calcitonin (SCT) 2 or 5 min-
utes after pentagastrin provocation with 0.5 \xg/kg body weight 
intravenously (normal SCT < 40 pmol/L) or an elevated basal 
calcitonin (BCT) level (normal BCT < 14 pmol/L). Patients 
were called converters if they initially had normal CT levels 
which rose to elevated CT levels during follow-up. For postop-
erative follow-up, a pentagastrin test was repeated shortly after 
surgery, after three months, after one year, and thereafter every 
year. If BCT was clearly and repeatedly abnormal, further pen-
tagastrin testing was usually omitted. "Normal CT levels" 
means both BCT and SCT are normal. "Elevated CT levels" 
may refer to either SCT alone or, as was the ca,se in most of the 
patients, both BCT and SCT 
Results 
Outcome of primary treatment 
Twenty-five patients in group 2 and 12 patients in group 1 
had an elevated CT level preoperatively. In six patients, among 
them two index cases in group 2, preoperative CT levels were 
not known (Table 1). 
Five patients in group 1 and 12 patients in group 2 were found 
to have normal CT levels postoperatively (Table 2). In these pa-
tients usually only the central lymph nodes had been removed; 
in two patients in group 2 a limited lateral dissection by picking 
out of suspicious nodes (which on histological examination 
proved to contain no tumor) was done and one patient in this 
group had a single lymph node biopsy only. In both groups all 
but one of the patients with normal postoperative CT levels ap-
peared to be node-negative (Table 3). The one patient in group 1 
who underwent a unilateral MRND because of one positive 
paratracheal node appeared to have no further lymph node me-
tastases. Afterwards he suffered neurapraxia of the hypoglossal 
nerve, as well as impaired shoulder function. The apparently 
cured node-positive (Nl) patient in group 2 only underwent bi-
lateral picking out of nodes. In the apparently node-negative 
(NO) group, postoperative CT levels remained elevated in some 
patients: three in group 1 and four in group 2. Also in group 2, 
two patients with initially normalized CT levels (one with ho-
molateral lymph node metastasis, one node-negative) showed 
an increasing CT level after several years (Table 4). On the other 
hand, one N1 patient in group 2 demonstrated spontaneous late 
normalization of CT levels (Figure): BCT remained normal af-
ter two years, SCT remained less than 40 pmol/L after three 
years and became undetectable after seven years. Ofthe two pa-
tients who underwent primary MRND in this group, one devel-
oped a persistent hypoparathyroidism. 
Secondary treatment 
Of the four patients in group 1 in whom only central lymph 
nodes were removed and who had elevated postoperative CT 
levels, one had additional MRND. Also, three patients (in whom 
lymph node surgery at primary operation was limited to taking a 
biopsy which on histological examination proved to contain tu-
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Lymph Node Stage in Relation to Postoperative CT Level 
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Figure—Follow-up CT levels in one patient who showed spon-
taneous normalization after more than seven years. Solid cir-
cles = basal CT, open circles = stimulated CT. 
mor) underwent secondary MRND. Unfortunately, despite re-
moval of tumor-positive nodes, MRND was not successful in 
any of them. CT levels did not normalize, and the patients died 
during follow-up (Tables 2 and 4). Postoperatively, one patient 
had diminished shoulder function due to damage of the acces-
sory nerve and one patient had bilateral and two unilateral paral-
ysis of the vocal chords. One of these also had a large hemor-
rhage in the operative field. 
In group 2, one Nl patient with a high postoperative CT level 
underwent additional bilateral MRND immediately after pri-
mary operation, whereafter CT normalized. Two positive lymph 
nodes containing micrometastases were found in the dissection 
material. In two other patients who had .secondary MRND seven 
and eight years after primary operation because of increasing 
BCT. the intervention was less successful with CT levels failing 
to normalize afterwards. There were no serious complications 
after MRND in this group. 
Survival and long-term follow-up 
In group 1, only four patients were still alive in 1991, a mean 
of 12.3 years after operation (range 8 to 16 years). These patients 
all had normal postoperative CT values (Table 4). One of them 
had undergone an MRND because of one homolateral positive 
lymph node (Table 2); the others were node-negative. Twelve 
patients in this group died after a mean of 38 ± 25 months; eight 
died of the disease, three of unknown causes (in one of them 
probably old age), and one patient with normal postoperative 
CT died of a metastasized breast carcinoma without evidence of 
MTC. 
In group 2, only one patient died of the disease with extensive 
liver and bone metastases nine years after operation. He had ele-
vated CT levels after operation. The other 26 patients are alive 
after a mean follow-up of 11 ± 1.8 years (range 8 to 16 years). 
Twelve of them have normal CT levels and are doing well, 
among them two patients who initially had elevated postopera-
tive CT levels: one with spontaneous conversion (Figure) and 
one with normalization after additional MRND shortly after pri-
mary operation. Fourteen patients presently have elevated CT 
Group I Group 2 
CT CT CT CT 
Normal Elevated Normal Elevated 
NO 4 3 11 4 
Nl 1 8 1 1 1 
Total 5 11 12 15 
Table 4 
Latest CT Levels at Follow-up in Relation 
to Postoperative CT Levels 
Group I Group 2 
CT CT CJ CT 
Normal Elevated Normal Elevated 
Latest follow-up: 
CT level normal 5* — 10 2 
CT level elevated l i t 2 13* 
Total 5 11 12 15 
*One patient died of metastastized breast carcinoma. 
tAll died during follow-up. 
tOne patient died with extensive lymph node, liver, and bone metastasis of MTC. 
levels, including two patients who had normal CT levels imme-
diately after operation, the two with primary MRND, and the 
two with additional MRND several years after primary opera-
tion. Of these 14, six patients have BCT levels of more than 400 
pmol/L. One of them has residual local tumor as well as liver 
metastases; one already had histologically proven liver metasta-
ses in 1964, 15 years before her thyroid operation (17), and is 
clinically not deteriorating; and one seems to have rapidly pro-
gressive liver metastasis. In the other three, as well as in the 
eight patients with BCT levels between 14 and 400 pmol/L, no 
other evidence of metastasis is currently demonstrable. 
Discussion 
In this retrospective study we have tried to assess the value of 
MRND in patients with MTC in our clinic by reviewing the out-
come ofthe patients operated on from 8 to 16 years ago. At that 
time, it was not the usual practice to perform elective MRND, so 
we do not have enough data to draw valid conclusions on its effi-
cacy from our material. Our results therefore are limited to the 
outcome of secondary MRND, as well as long-term follow-up 
of those patients who did not undergo MRND. 
A large difference in survival was seen between our two 
groups. There are two reasons for this. First, five-year survival 
in group 1 was in fact dramatically low compared to rates re-
ported in the literature (1), probably because several patients in 
group 1 were of an advanced age at the time of diagnosis (four 
patients were well over age 75 years). Second, tumor stage was 
more advanced in group 1; all patients presented with a palpable 
swelling, and in three a radical operation was no longer possible. 
Another difference between the two groups was that a normal 
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postoperative CT level in group 1 was clearly related to a good 
prognosis, whereas in group 2 this was less evident because two 
patients showed late conversion to elevated levels and one pa-
tient showed spontaneous normalization. In other words, CT 
levels in group 2 followed a much less predictable course than in 
group 1. 
Because in our MEN 2 group there were four patients (among 
them one so-called converter) apparently without lymph node 
involvement who were found to have elevated postoperative CT 
levels (Table 3), it would be tempting to conclude that a primary 
elective bilateral MRND should be done in all MEN patients re-
gardless of lymph node stage. However, our data seem to indi-
cate a better correlation of treatment success with lymph node 
stage than with the extent of lymph node dissection; in none of 
our patients with normal postoperative CT levels could this be 
attributed to an extensive primary lymph node dissection (Ta-
bles 2 and 3), while on the other hand none of the patients with 
extensive lymph node involvement (i.e., more than five positive 
nodes) became tumor-free. This corresponds with the findings 
of Samaan et al (18) who studied a group of patients with MTC 
limited to the thyroid (NO) and found no difference in outcome 
between those who had or did not have MRND. Furthermore, 
Russell et al (8) found no difference in survival in the group with 
an advanced tumor stage between the patients who were treated 
with a limited operation and those who had a more radical 
lymph node resection. 
The clinical course of our patients with elevated CT levels 
tends to be benign: few patients have symptoms, few patients 
have demonstrable tumor, and only one patient has died. This 
"dormant course" of the tumor has also been reported by others 
(10,19). Still we must keep in mind that these are young patients 
and overall life expectancy may be reduced; tumor metastasis 
might be detected many years after operation. 
At present, treatment of tumor relapse and especially of me-
tastasis is not satisfactory (20-23), although promising results 
have been seen with ' -^ ' I MIBG (24). 
Normalization of CT levels has been reported after removal 
of residual lymph node metastases localized to the neck by care-
ful secondary MRND (14,25), but no data on long-term follow-
up are available yet. Looking closely at the results of Tisell et al 
(14), it is remarkable that only patients with six or less positive 
nodes at secondary dissection were cured. Several other authors 
report less favorable results (10,19,26,27), although this may 
partly depend on a difference in technique and patient selection. 
Raue et al (26) saw a better 5-year survival rate in their group 
with reintervention, although only twice was normalization of 
CT levels obtained; however, their groups do not appear to be 
comparable because in the group without reintervention there 
were six patients with an advanced stage of the disease. Low 
success rates at secondary MRND might also be due to (occult) 
hepatic metastases, which have been shown to occur early in the 
course of the disease (28). This could also be the explanation for 
our finding that several apparently node-negative patients 
tumed out to have elevated CT levels postoperatively. 
In conclusion, although several authors advise primary elec-
tive MRND in patients with MTC, our data do not support these 
recommendations. None of our patients became CT-negative as 
a result of extensive primary lymph node surgery, but rather be-
cause of a favorable tumor stage. CT levels in all but two of the 
patients with normal postoperative CT levels remained normal, 
and one patient with elevated postoperative CT even showed 
spontaneous normalization. In our material, only one of seven 
secondary MRNDs was successful; this patient was found to 
have two additional positive nodes. Many complications were 
seen after MRND. Nevertheless, in the absence of effective ther-
apies other than surgery, there seems to be a small group of pa-
tients who potentially benefit from curative MRND. To prevent 
overtreatment, we would advise a systematic lymph node dis-
section of the central compartment at primary operation, with 
extension towards an MRND only if (micro)metastases are 
identified. If postoperative CT levels remain elevated in patients 
who did not undergo extensive primary lymph node dissection, 
additional (secondary) MRND should be considered. The value 
of this procedure remains unproven. In our opinion, it is ques-
tionable whether extensive lymph node surgery improves sur-
vival of patients with extensive (e.g., ten or more) lymph node 
metastases. 
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